IP Library › Granted Patent US 12,378,556
Granted Patent B2
US 12,378,556 · App. 17/156,421 · Granted Aug 5, 2025

Treatment of angiopoietin like 7 (ANGPTL7) related diseases

Inventors: Omri Gottesman (San Diego, CA); Shannon Bruse (San Diego, CA); Paul Buske (Madison, WI); Brian Cajes (San Diego, CA); David Lewis (Madison, WI); David Rozema (Cross Plains, WI)
Assignee: EMPIRICO INC.
C12N15/1136A61P27/06C12N2310/14C12N2310/315C12N2310/321C12N2310/322C12N2310/3515
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,378,556
App. No.
17/156,421
Granted
Aug 5, 2025
Kind
B2
Abstract

Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.

Claims (19)

1. A method of treating an ocular disorder in a subject in need thereof, comprising administering to the subject a composition comprising an oligonucleotide that targets Angiopoietin like 7 (ANGPTL7) and when administered to a cell decreases expression of ANGPTL7, wherein the oligonucleotide comprises a small interfering RNA (siRNA) comprising a sense strand and an antisense strand, wherein the sense strand comprises an oligonucleotide sequence of SEQ ID NOs: 948, 1424, 1541, or 2091 in which at least one internucleoside linkage is modified and at least one nucleoside is modified, or an oligonucleotide sequence comprising 1 or 2 nucleoside substitutions, additions, or deletions of SEQ ID NOs: 948, 1424, 1541, or 2091 in which at least one internucleoside linkage is modified and at least one nucleoside is modified, and wherein the antisense strand comprises an oligonucleotide sequence of SEQ ID NOs: 3154, 3630, 3747, or 4297 in which at least one internucleoside linkage is modified and at least one nucleoside is modified, or an oligonucleotide sequence comprising 1 or 2 nucleoside substitutions, additions, or deletions of SEQ ID NOs: 3154, 3630, 3747, or 4297 in which at least one internucleoside linkage is modified and at least one nucleoside is modified, wherein the ocular disorder comprises glaucoma or ocular hypertension, and wherein the administering to the subject the composition comprises administering the composition to the subject by an ocular route.

2. The method of claim 1 , wherein the at least one nucleoside that is modified comprises a 2′-fluoro modified nucleoside.

3. The method of claim 1 , wherein the at least one nucleoside that is modified comprises a 2′-O-methyl modified nucleoside.

4. The method of claim 1 , wherein the oligonucleotide comprises 15-23 modified nucleosides.

5. The method of claim 4 , wherein the 15-23 modified nucleosides comprise 2′-fluoro modified nucleosides and 2′-O-methyl modified nucleosides.

6. The method of claim 1 , wherein the at least one internucleoside linkage that is modified comprises a phosphorothioate linkage.

7. The method of claim 1 , wherein the oligonucleotide comprises a lipid attached at a 3′ or 5′ terminus of the oligonucleotide.

8. The method of claim 7 , wherein the lipid comprises cholesterol, myristoyl, palmitoyl, stearoyl, lithocholoyl, docosanoyl, docosahexaenoyl, myristyl, palmityl stearyl, or α-tocopherol, or a combination thereof.

9. The method of claim 8 , wherein the lipid is attached to the 3′ terminus of the sense strand.

10. The method of claim 9 , wherein the lipid comprises cholesterol.

11. The method of claim 1 , wherein the sense strand comprises an oligonucleotide sequence of SEQ ID NO: 11186 and the antisense strand comprises an oligonucleotide sequence of SEQ ID NO: 11306.

12. The method of claim 1 , wherein the sense strand comprises an oligonucleotide sequence of SEQ ID NO: 11211 and the antisense strand comprises an oligonucleotide sequence of SEQ ID NO: 11331.

13. The method of claim 1 , wherein the sense strand comprises an oligonucleotide sequence of SEQ ID NO: 948 and modification pattern 1S, and the antisense strand comprises an oligonucleotide sequence of SEQ ID NO: 3154 and modification pattern 1AS.

14. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable excipient.

15. The method of claim 1 , wherein the composition decreases intraocular pressure in an eye of the subject relative to a baseline intraocular pressure measurement obtained from the subject prior to administering the composition to the subject.

16. The method of claim 15 , wherein the composition decreases intraocular pressure in the eye of the subject by at least 10% relative to the baseline intraocular pressure measurement obtained from the subject prior to administering the composition to the subject.

17. The method of claim 1 , wherein the ocular route comprises topical administration or intraocular injection.

18. The method of claim 17 , wherein the topical administration comprises a formulation of eye drops, cream, ointment, gel, or salve.

19. The method of claim 17 , wherein the intraocular injection comprises a subconjunctival, periocular, periocular conjunctival fornix, intravitreal, intracameral, or retrobulbar injection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2021
From: GOTTESMAN, OMRI; BRUSE, SHANNON; BUSKE, PAUL; CAJES, BRIAN; LEWIS, DAVID; ROZEMA, DAVID
To: EMPIRICO INC.
Reel/Frame 055128/0764 →
Continuity (5)
Continuation 17012524 · Sep 4, 2020
Continuation PCTUS2020034063 · May 21, 2020
Provisional Application 62881906 · Aug 1, 2019
Provisional Application 62852813 · May 24, 2019
Related Publication 20210163950A1 · Jun 3, 2021
References Cited (62)
US 543227A · Benner · 1895 [cited by applicant]
US 7691997B2 · Khvorova et al. · 2010 [cited by applicant]
US 8090542B2 · Khvorova · 2012 [cited by examiner]
US 9206423B2 · Russell et al. · 2015 [cited by applicant]
US 9796974B2 · Rajeev et al. · 2017 [cited by applicant]
US 9920320B2 · Russell et al. · 2018 [cited by applicant]
US 10053694B2 · Lee et al. · 2018 [cited by applicant]
US 10668170B2 · Rajeev et al. · 2020 [cited by applicant]
US 10941404B2 · Gottesman et al. · 2021 [cited by applicant]
US 20040198640A1 · Leake et al. · 2004 [cited by applicant]
US 20050080246A1 · Allerson et al. · 2005 [cited by applicant]
US 20060148743A1 · Jadhav et al. · 2006 [cited by applicant]
US 20080038202A1 · Zhao et al. · 2008 [cited by applicant]
US 20090137507A1 · McSwiggen et al. · 2009 [cited by applicant]
US 20110150897A1 · Meyer et al. · 2011 [cited by applicant]
US 20150174203A1 · Chen et al. · 2015 [cited by applicant]
US 20160264969A1 · Patel et al. · 2016 [cited by applicant]
US 20180105563A1 · Usui et al. · 2018 [cited by applicant]
US 20180177847A1 · Chen et al. · 2018 [cited by applicant]
US 20200399640A1 · Gottesman et al. · 2020 [cited by applicant]
US 20220089664A1 · Praveen et al. · 2022 [cited by applicant]
US 20230357774A1 · Gottesman et al. · 2023 [cited by applicant]
EP 2213738A2 · 2010 [cited by applicant]
WO WO9302093A1 · 1993 [cited by applicant]
WO WO2010093816A2 · 2010 [cited by applicant]
WO WO2011051276A1 · 2011 [cited by applicant]
WO WO2014167529A1 · 2014 [cited by applicant]
WO WO2015106128A2 · 2015 [cited by applicant]
WO WO2018201090A1 · 2018 [cited by applicant]
WO WO2019161213A1 · 2019 [cited by applicant]
WO WO2020142693A1 · 2020 [cited by applicant]
WO WO2020154268A2 · 2020 [cited by applicant]
WO WO2020242896A2 · 2020 [cited by applicant]
WO WO2022031433A1 · 2022 [cited by applicant]
WO WO2022072356A1 · 2022 [cited by applicant]
WO WO2023192828A2 · 2023 [cited by applicant]
Praveen, K., Patel, G.C., Gurski, L. et al. ANGPTL7, a therapeutic target for increased intraocular pressure and glaucoma. Commun Biol 5, 1051 (2022). https://doi.org/10.1038/s42003-022-03932-6 (Year: 2022). [cited by examiner]
Fitzpatrick et al., Developmental eye disorders, Current Opinion in Genetics & Development 2005, 15:348-353 (Year: 2005). [cited by examiner]
Vicentini et al., Delivery systems and local administration routes for therapeutic siRNA, 2013, Pharm. Res., 30, 915-931. (Year: 2013). [cited by examiner]
Battacharya et al.: Proteomics Reveal Cochlin Deposits Associated with Glaucomatous Trabecular Meshwork. J. Biol. Chem. 280(7):6080-6084 (2005). [cited by applicant]
Comes et al.: Individual molecule response to elevated intraocular pressure in perfused postmortem human eyes. Physiol. Genomics 38:205-225 (2009). [cited by applicant]
Comes et al., Evidence for a role of angiopoietin-like 7 (ANGPTL7) in extracellular matrix formation of the human trabecular meshwork: implications for glaucoma. Genes to Cells 16(2):243-259 (2011). [cited by applicant]
Kuchtey et al., Angiopoietin-like 7 secretion is induced by glaucoma stimuli and its concentration is elevated in glaucomatous aqueous humor. Investigative Ophthalmology and Visual Science 49(8):3438-3448 (2008). [cited by applicant]
PCT/US2020/034063 International Search Report and Written Opinion dated Dec. 9, 2020. [cited by applicant]
PCT/US2020/034063 Invitation to Pay Additional Fees dated Aug. 21, 2020. [cited by applicant]
Rozsa et al.: Gene expression profile of human trabecular meshwork cells in response to long-term dexamethasone exposure. Molecular Vision. 125-141 (2006). [cited by applicant]
Santa Cruz Biotechnology, Inc.: Angptl7 siRNA (h): sc-88201 (1 page) https://datasheets.scbt.com/sc-88201.pdf (2019). [cited by applicant]
Toyono et al.: Angiopoietin-Like 7 Is an Anti-Angiogenic Protein Required to Prevent Vascularization of the Cornea. PLoS One. DOI: 10.1371/journal.pone.0116838 (2015). [cited by applicant]
U.S. Appl. No. 17/012,524 First Action Interview dated Nov. 10, 2020. [cited by applicant]
PCT/US2021/052424 International Invitation to Pay Additional Fees dated Dec. 13, 2021. [cited by applicant]
PCT/US2021/052424 International Search Report and Written Opinion dated Feb. 17, 2022. [cited by applicant]
Tanigawa et al.: Rare protein-altering variants in ANGPTL7 lower intraocular pressure and protect against glaucoma. PLoS Genet. 16(5):e1008682 (2020). [cited by applicant]
Buie et al.: Angiopoietin-like 7 (ANGPTL7) Modulates DEX Induction and Fibronectin (FN1) Fibrils Formation in the Human Trabecular Meshwork (HTM)—ARVO Annual Meeting Abstract. Investigative Ophthalmology & Visual Scienc… [cited by applicant]
EP20813437.9 Partial European Search Report dated Nov. 17, 2023. [cited by applicant]
PCT/US2023/064997 Invitation to Pay Additional Fees dated Jul. 17, 2023. [cited by applicant]
Chemical Abstracts Service. CAS Registry: 114616-27-2. MMT-Hexylaminolinker Phosphoramidite: pp. 1-9. STN Entry Date Sep. 25, 2006. Retrieved Oct. 11, 2024. Retrieved from: https://pubchem.ncbi.nlm.nih.gov/compound/9873… [cited by applicant]
Chemical Abstracts Service. CAS Registry: 178925-21-8. Amino-Modifier C6 dT: pp. 1-4. STN Entry Date Feb. 18, 2024. Retrieved Oct. 11, 2024. Retrieved from :https://pubchem.ncbi.nlm.nih.gov/substance/488407216. [cited by applicant]
Cheng, Angie et al. Stem-loop RT-PCR quantification of siRNAs in vitro and in vivo. Oligonucleotides 19(2):203-208 (2009). [cited by applicant]
Database Accession No. HD836236. Sequence 712952 from EP2213738 (2010). [cited by applicant]
EP20813437.9 European Search Report dated Aug. 13, 2024. [cited by applicant]
PCT/US2023/064997 International Preliminary Report on Patentability dated Oct. 10, 2024. [cited by applicant]
PCT/US2023/064997 International Search Report and Written Opinion dated Sep. 29, 2023. [cited by applicant]